This site is my collection of updates, statistics and analysis on intellectual property in Canada. I am a partner at DLA Piper (Canada) LLP practicing in the area of intellectual property (more about me). Material on this website are my own views and do not reflect the position of DLA Piper (Canada) LLP, any of its member firms around the world, or any of its clients. IPPractice.ca grew out of my hobby to gather and share interesting updates on intellectual property to friends and colleagues. Highlights include:
The various amendments relating to the Patented Medicines Prices Review Board mentioned in my update earlier this week have now been published in the Canada Gazette Part 2.
Various amendments relating to the Patented Medicines Prices Review Board are to come into force on June 30, 2021 including amendments to sections 79 to 103 of the Patent Act. In addition there are some changes being made for consistency with the Patent Act and to encompass CSPs. This is in addition to the amended Patented Medicines Regulations expanding reporting requirements are scheduled to come into force July 1, 2021 after being delayed several times. …Read More
The Federal Court of Appeal, in a new Practice Notice “Electronic Service of Documents for the duration of the Suspension Period”, makes electronic service by email permissible in all cases and requires email addresses be added to all documents filed with the Federal Court of Appeal, with limited exceptions, while the, now indefinite, Suspension Period is in effect.
The Federal Court has published revised consolidated intellectual property guidance for case management and trial management. The Court has included a blackline version which indicates that changes include limiting “second round” discovery, use of claim charts, compendia and slide decks at trial and requests to admit.
Earlier today, the USPTO issued patent 11,000,000. Since the USPTO granted US10,000,000 about three years ago, the Canadian Patent Office issued about 64,000 patents.